Ivacaftor has 20 known drug interactions based on U.S. FDA drug labeling data. 12 are classified as major interactions requiring close medical supervision. Notable interactions include combinations with Carbamazepine, Clarithromycin, Itraconazole. Patients taking Ivacaftor should inform their healthcare provider of all current medications — including over-the-counter drugs and supplements — to avoid potentially harmful combinations. Data sourced from OpenFDA and the NIH National Library of Medicine.
- Total
- 20
- Major
- 12
- Moderate
- 6
- Minor
- 1
Major (12)
- Ivacaftor + Carbamazepine— Strong CYP3A inducer. Co-administration not recommended.
- Ivacaftor + Clarithromycin— Strong CYP3A inhibitor. Dosage reduction recommended for patients ≥6 months; not recommended for patients <6 months.
- Ivacaftor + Itraconazole— Strong CYP3A inhibitor. Dosage reduction recommended for patients ≥6 months; not recommended for patients <6 months.
- Ivacaftor + Ketoconazole— Strong CYP3A inhibitor significantly increased ivacaftor exposure 8.5-fold. Dosage reduction recommended for patients ≥6…
- Ivacaftor + Phenobarbital— Strong CYP3A inducer. Co-administration not recommended.
- Ivacaftor + Phenytoin— Strong CYP3A inducer. Co-administration not recommended.
- Ivacaftor + Posaconazole— Strong CYP3A inhibitor. Dosage reduction recommended for patients ≥6 months; not recommended for patients <6 months.
- Ivacaftor + Rifabutin— Strong CYP3A inducer. Co-administration not recommended.
- Ivacaftor + Rifampin— Strong CYP3A inducer significantly decreased ivacaftor exposure approximately 9-fold. Co-administration not recommended.
- Ivacaftor + St. John'S Wort— Strong CYP3A inducer. Co-administration not recommended.
- Ivacaftor + Telithromycin— Strong CYP3A inhibitor. Dosage reduction recommended for patients ≥6 months; not recommended for patients <6 months.
- Ivacaftor + Voriconazole— Strong CYP3A inhibitor. Dosage reduction recommended for patients ≥6 months; not recommended for patients <6 months.
Moderate (6)
- Ivacaftor + Erythromycin— Therefore, a reduction of the KALYDECO dosage is recommended for patients aged 6 months and older taking concomitant mod…
- Ivacaftor + Fluconazole— 7 DRUG INTERACTIONS Potential for other drugs to affect ivacaftor CYP3A inhibitors: Reduce KALYDECO dosage in patients a…
- Ivacaftor + Glimepiride— Ivacaftor may increase glimepiride exposure through CYP2C9 inhibition. Should be used with caution.
- Ivacaftor + Glipizide— Ivacaftor may increase glipizide exposure through CYP2C9 inhibition. Should be used with caution.
- Ivacaftor + Grapefruit Products— Grapefruit contains components that moderately inhibit CYP3A and may increase ivacaftor exposure. Avoid food or drink co…
- Ivacaftor + Warfarin— Ivacaftor may inhibit CYP2C9, potentially increasing warfarin exposure. INR monitoring recommended during concomitant us…
Minor (1)
- Ivacaftor + Ciprofloxacin— Co-administration had no effect on ivacaftor exposure. No dosage adjustment necessary.